These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19739879)

  • 21. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
    Jung JA; Kaku K; Kim JH; Kim JR; Ko JW; Lee SY; Huh W
    Adv Ther; 2013 Nov; 30(11):1018-29. PubMed ID: 24249434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
    Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM; Wysham C; Macconell L; Malloy J; Walsh B; Yan P; Wilhelm K; Malone J; Porter LE;
    Lancet; 2010 Aug; 376(9739):431-9. PubMed ID: 20580422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic.
    Kleinow ME; Garwood CL; Clemente JL; Whittaker P
    J Manag Care Pharm; 2011 Sep; 17(7):523-30. PubMed ID: 21870893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
    Eurich DT; Simpson S; Senthilselvan A; Asche CV; Sandhu-Minhas JK; McAlister FA
    BMJ; 2013 Apr; 346():f2267. PubMed ID: 23618722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z
    Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
    Aschner P; Katzeff HL; Guo H; Sunga S; Williams-Herman D; Kaufman KD; Goldstein BJ;
    Diabetes Obes Metab; 2010 Mar; 12(3):252-61. PubMed ID: 20070351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus.
    Chen TY; Hsieh CJ
    Postgrad Med; 2014 May; 126(3):205-15. PubMed ID: 24918804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
    Chan JC; Scott R; Arjona Ferreira JC; Sheng D; Gonzalez E; Davies MJ; Stein PP; Kaufman KD; Amatruda JM; Williams-Herman D
    Diabetes Obes Metab; 2008 Jul; 10(7):545-55. PubMed ID: 18518892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.
    Strøm Halden TA; Åsberg A; Vik K; Hartmann A; Jenssen T
    Nephrol Dial Transplant; 2014 Apr; 29(4):926-33. PubMed ID: 24452849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Vilsbøll T; Rosenstock J; Yki-Järvinen H; Cefalu WT; Chen Y; Luo E; Musser B; Andryuk PJ; Ling Y; Kaufman KD; Amatruda JM; Engel SS; Katz L
    Diabetes Obes Metab; 2010 Feb; 12(2):167-77. PubMed ID: 20092585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
    Ferrannini E; Berk A; Hantel S; Pinnetti S; Hach T; Woerle HJ; Broedl UC
    Diabetes Care; 2013 Dec; 36(12):4015-21. PubMed ID: 24186878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Arai K; Maeda H; Sirabe S; Yamamoto R; Yamauchi M; Hirao T; Hirao S; Hirao K
    Diabetes Technol Ther; 2013 Apr; 15(4):335-41. PubMed ID: 23480592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study.
    Henry RR; Staels B; Fonseca VA; Chou MZ; Teng R; Golm GT; Langdon RB; Kaufman KD; Steinberg H; Goldstein BJ
    Diabetes Obes Metab; 2014 Mar; 16(3):223-30. PubMed ID: 23909985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
    Koren S; Shemesh-Bar L; Tirosh A; Peleg RK; Berman S; Hamad RA; Vinker S; Golik A; Efrati S
    Diabetes Technol Ther; 2012 Jul; 14(7):561-7. PubMed ID: 22512265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Iwamoto Y; Taniguchi T; Nonaka K; Okamoto T; Okuyama K; Arjona Ferreira JC; Amatruda J
    Endocr J; 2010; 57(5):383-94. PubMed ID: 20332588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
    Davies M; Pratley R; Hammer M; Thomsen AB; Cuddihy R
    Diabet Med; 2011 Mar; 28(3):333-7. PubMed ID: 21309842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
    Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
    Violante R; Oliveira JH; Yoon KH; Reed VA; Yu MB; Bachmann OP; Lüdemann J; Chan JY
    Diabet Med; 2012 Nov; 29(11):e417-24. PubMed ID: 22375612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.